Emyria Ltd (ASX:EMD) Michael Winlo tells Proactive the company has been accepted into the US National Institute of Health’s (NIH) Preclinical Screening Platform for Pain program. The NIH’s National Institute of Neurological Disorders and Stroke (NINDS) � also the leading funder of neurological research in the US will run the study as part of a broader initiative to stem the opioid public health crisis.
Hashtag: #Emyria
The issuer is solely responsible for the content of this announcement.
An iterative process is highly effective in increasing the value of large items HONG KONG…
HOHHOT, CHINA - Media OutReach Newswire - 7 November 2024 - In Q4 2024, the…
TAIPEI, TAIWAN - Media OutReach Newswire - 7 November 2024 - TVBS is a leading…
Redefining the Golden Years with “Care Food” HONG KONG SAR - Media OutReach Newswire -…
TAIPEI, TAIWAN - Media OutReach Newswire - 7 November 2024 - The UK's Competition and…
PHNOM PENH, CAMBODIA - Media OutReach Newswire - 7 November 2024 - The way people…